Linee guida

ACG clinical guideline: the diagnosis and management of focal liver lesions.Marrero JA, Ahn J, Rajender Reddy K; Americal College of Gastroenterology. Am J Gastroenterol. 2014 Sep;109(9):1328-47

Focal liver lesions (FLL) have been a common reason for consultation faced by gastroenterologists and hepatologists. The increasing and widespread use of imaging studies has led to an increase in detection of incidental FLL.

ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury.Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ; Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 2014 Jul;109(7):950-66

 

Idiosyncratic drug-induced liver injury (DILI) is a rare adverse drug reaction and it can lead to jaundice, liver failure, or even death. Antimicrobials and herbal and dietary supplements are among the most common therapeutic classes to cause DILI in the Western world. DILI is a diagnosis of exclusion and thus careful history taking and thorough work-up for competing etiologies are essential for its timely diagnosis.

Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.Paul Martin, Andrea DiMartini, Sandy Feng, Robert Brown Jr. And Michael Fallon .Hepatology  2014 Article first published online: 25 FEB 2014

Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Updated June 2014.Dumonceau JM, Andriulli A, Elmunzer BJ, Mariani A, Meister T, Deviere J, Marek T, Baron TH, Hassan C, Testoni PA, Kapral C. Endoscopy. 2014 Sep;46(9):799-815. 

 

This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). It addresses the prophylaxis of post-endoscopic retrograde cholangiopancreatography (post-ERCP) pancreatitis.

Review article: 2014 UK consensus guidelines – hepatitis C management and direct-acting anti-viral therapy.M. H. Miller,K. Agarwal, A. Austin, A. Brown, S. T. Barclay, P. Dundas, G. M. Dusheiko, G. R. Foster, R. Fox, P. C. Hayes, C. Leen, C. Millson, S. D. Ryder, J. Tait, A. Ustianowski and J. F. Dillon .Alimentary Pharmacology & Therapeutics 2014 Article first published online: 22 APR 2014

Background

Therapeutic options for the management of hepatitis C virus (HCV) infection have evolved rapidly over the past two decades, with a consequent improvement in cure rates. Novel therapeutic agents are an area of great interest in the research community, with a number of these agents showing promise in the clinical setting.

Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver.Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatology. 2014 Aug;60(2):715-35. Epub 2014 Jul 8.

Additional information